SCHEMBL6314712

SCHEMBL6314712

Cn1c(=O)c2nc(C=O)cnc2n(C)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
MAPT P10636 2/20 0.49
KDM4E B2RXH2 7/20 0.48
HSD17B10 Q99714 3/20 0.48
LMNA P02545 2/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48
HPGD P15428 3/20 0.47
HTT P42858 2/20 0.47
JAK2 O60674 1/20 0.47
PAX8 Q06710 1/20 0.47
GAA P10253 3/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
RECQL P46063 1/20 0.45
ADORA2A P29274 3/20 0.42
GLA P06280 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
PIK3CD O00329 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317891 0.87 ALDH1A1 (0.47) ALDH1A1MAPTKDM4EHSD17B10LMNA
SCHEMBL6315474 0.79 KDM4E (0.53) ALDH1A1MAPTKDM4EHSD17B10LMNA
SCHEMBL6314656 0.79 KDM4E (0.45) ALDH1A1MAPTKDM4EHSD17B10LMNA
SCHEMBL5440337 0.79 KDM4E (0.53) ALDH1A1MAPTKDM4EHSD17B10LMNA
SCHEMBL5445042 0.78 KDM4E (0.56) ALDH1A1MAPTKDM4EHSD17B10LMNA
SCHEMBL6316300 0.78 KDM4E (0.44) ALDH1A1MAPTKDM4EHSD17B10LMNA
SCHEMBL6315801 0.77 ALDH1A1 (0.51) ALDH1A1MAPTKDM4EHSD17B10LMNA
SCHEMBL5439523 0.77 KDM4E (0.58) ALDH1A1MAPTKDM4EHSD17B10LMNA
SCHEMBL5440119 0.77 ALDH1A1 (0.51) ALDH1A1MAPTKDM4EHSD17B10LMNA
SCHEMBL6316569 0.77 TNF (0.47) ALDH1A1MAPTKDM4EHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US disclosed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US disclosed
EP-1187615-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. Leuven Research & Development (BE) 2002-03-20 EP disclosed
WO-2000045800-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives TPMT, FKBP5, RRP15 ALDH1A1 1744/4885MAPT 388/4885KDM4E 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.